Stocks / NASDAQ / Grace Therapeutics Inc.

Grace Therapeutics Inc.

Industry: Health Care – Biotechnology: Pharmaceutical Preparations

Stock Symbol: GRCE – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Grace Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company confirms on its website that it utilizes animal subjects for product testing.

“Grace is committed to minimizing animal testing by sharing data when feasible. When legally required to submit animal testing data to a government authority, we work together with other companies producing or importing the same chemical substance to share information on the intrinsic properties of the chemical at issue and to jointly submit the information. In addition, Grace actively shares its data with third parties, applying fair and transparent conditions.” Read the following article

Company Description

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Company Website: https://www.gracetx.com

Contact: info@gracetx.com